menu
    • menu
    [{"orgOrder":0,"company":"Opsona Therapeutics Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"OPN-305","moa":"Toll-like receptor 2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Opsona Therapeutics Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Opsona Therapeutics Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Opsona Therapeutics Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Opsona Therapeutics Ltd","sponsor":"MD Anderson Cancer Center | Montefiore Medical Center | Moffitt Cancer Center | New York Presbyterian Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"OPN-305","moa":"Toll-like receptor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Opsona Therapeutics Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Opsona Therapeutics Ltd \/ MD Anderson Cancer Center | Montefiore Medical Center | Moffitt Cancer Center | New York Presbyterian Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Opsona Therapeutics Ltd \/ MD Anderson Cancer Center | Montefiore Medical Center | Moffitt Cancer Center | New York Presbyterian Hospital"},{"orgOrder":0,"company":"Opsona Therapeutics Ltd","sponsor":"MD Anderson Cancer Center | Montefiore Medical Center | Moffitt Cancer Center | New York Presbyterian Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"OPN-305","moa":"Toll-like receptor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Opsona Therapeutics Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Opsona Therapeutics Ltd \/ MD Anderson Cancer Center | Montefiore Medical Center | Moffitt Cancer Center | New York Presbyterian Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Opsona Therapeutics Ltd \/ MD Anderson Cancer Center | Montefiore Medical Center | Moffitt Cancer Center | New York Presbyterian Hospital"}]

    Find Clinical Drug Pipeline Developments & Deals by Opsona Therapeutics Ltd

    Menu

    Opsona Therapeutics Ltd

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Opsona Therapeutics Ltd

                            Ireland arrow
                            AAPS
                            Not Confirmed

                            Opsona Therapeutics Ltd

                            Ireland arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OPN-305

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : MD Anderson Cancer Center | Montefiore Medical Center | Moffitt Cancer Center | New York Presbyterian Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Follow up Protocol to the Phase I/II Study of OPN-305 in Second-line or Third-line Lower Lower Risk Myelodyspl...

                            Details : OPN-305 is a Antibody drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Myelodysplastic Syndromes.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            November 09, 2017

                            Lead Product(s) : OPN-305

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : MD Anderson Cancer Center | Montefiore Medical Center | Moffitt Cancer Center | New York Presbyterian Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Opsona Therapeutics Ltd

                            Ireland arrow
                            AAPS
                            Not Confirmed

                            Opsona Therapeutics Ltd

                            Ireland arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OPN-305

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : MD Anderson Cancer Center | Montefiore Medical Center | Moffitt Cancer Center | New York Presbyterian Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome

                            Details : OPN-305 is a Antibody drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Myelodysplastic Syndromes.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            February 16, 2015

                            Lead Product(s) : OPN-305

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : MD Anderson Cancer Center | Montefiore Medical Center | Moffitt Cancer Center | New York Presbyterian Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Opsona Therapeutics Ltd

                            Ireland arrow
                            AAPS
                            Not Confirmed

                            Opsona Therapeutics Ltd

                            Ireland arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OPN-305

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Func...

                            Details : OPN-305 is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Delayed Graft Function.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            February 20, 2013

                            Lead Product(s) : OPN-305

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth